People with Down’s syndrome have an earlier and more substantial build-up of amyloid plaques and tau protein in the brain than people without the genetic condition, making them vulnerable to early Alzheimer’s disease.
The team has also developed a nanoparticle-delivered antibody that they hope could possibly address both triple-negative breast cancer (TNBC) metastasis and resistance to treatment. They estimate that the strategy of blocking the culprit gene, TRIM37, could benefit approximately 80% of TNBC patients.
Before patients can be treated with REGEN-COV2 under the EUA, they must weigh at least 40 kilograms (about 88 pounds) and be deemed at high risk for progressing to severe COVID-19 and/or hospitalization. That high-risk category includes adults who are ages 65 or older, or who have chronic medical conditions.
A study carried out by the Children's Hospital Los Angeles shows a high prevalence of the recent D614G variant and other mutations in children infected with SARS-CoV-2, as well as a high level of the 20C clade in severe cases.
The research suggested that the altered gut microbiome found in COPD patients could also support the gut as a potential target for new treatments.
The companies said final efficacy data announced earlier this week showing BNT162b2 to be 95% effective in Phase III trial in participants without prior SARS-CoV-2 infection will be presented in support of the application, along with positive safety data.
Low-level interferon signaling that offers antiviral protection in the absence of active infection is present in all humans shortly after birth, but where and how this signaling occurs has remained unclear. The newly reported work offers up an explanation for this phenomenon.
The research suggests the nature and outcome of medulloblastoma relapse are biology and therapy dependent, providing translational opportunities for improved disease management through ongoing surveillance, prognostication, and risk-stratified selection of second-line treatments.
Using a combination of proteomic analyses and DNA and RNA sequencing to profile breast cancer tumors could lead to more effective, tailored treatment, suggests research from the Broad Institute and Baylor College of Medicine.
By expressing neuron-enriched mitochondrial proteins at an early stage of the direct reprogramming process, the researchers achieved a four times higher conversion rate and simultaneously increased the speed of reprogramming.